These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 5311767)

  • 41. [Biochemistry of depression].
    Matussek N
    J Neural Transm; 1972; 33(3):223-34. PubMed ID: 4565920
    [No Abstract]   [Full Text] [Related]  

  • 42. EEG and urinary non-catecholic amine changes during L-dopa therapy of Parkinson's disease.
    Marjerrison G; Boulton AA; Rajput AH
    Dis Nerv Syst; 1972 Mar; 33(3):164-9. PubMed ID: 5022451
    [No Abstract]   [Full Text] [Related]  

  • 43. Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays.
    Morgan JP; Bianchine JR; Spiegel HE; Rivera-Calimlim L; Hersey RM
    Arch Neurol; 1971 Jul; 25(1):39-44. PubMed ID: 5146410
    [No Abstract]   [Full Text] [Related]  

  • 44. The effect of reserpine on catecholamine metabolism and behavior in retarded children.
    Anton AH
    Clin Pharmacol Ther; 1966; 7(6):727-39. PubMed ID: 5918009
    [No Abstract]   [Full Text] [Related]  

  • 45. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and Parkinsonian subjects.
    Jones DG; Turnbull MJ; Lenman JA; Robertson MA
    J Neurol Sci; 1972 Nov; 17(3):245-53. PubMed ID: 4653961
    [No Abstract]   [Full Text] [Related]  

  • 48. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
    Burkhard P; Dominici P; Borri-Voltattorni C; Jansonius JN; Malashkevich VN
    Nat Struct Biol; 2001 Nov; 8(11):963-7. PubMed ID: 11685243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
    Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
    [No Abstract]   [Full Text] [Related]  

  • 50. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
    Routh JI; Bannow RE; Fincham RW; Stoll JL
    Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
    [No Abstract]   [Full Text] [Related]  

  • 51. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K; Möller WD
    Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
    [No Abstract]   [Full Text] [Related]  

  • 52. Metabolism of 3,4-dihydroxyphenylalanine (L-dopa) in human subjects.
    Goodall M; Alton H
    Biochem Pharmacol; 1972 Sep; 21(17):2401-8. PubMed ID: 4647074
    [No Abstract]   [Full Text] [Related]  

  • 53. [On the problem of the metabolism of dopamine in the brain of patients with parkinsonism].
    Travenets IA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1966; 66(10):1505-7. PubMed ID: 6000312
    [No Abstract]   [Full Text] [Related]  

  • 54. Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings.
    Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    J Neural Transm; 1974; 35(2):93-116. PubMed ID: 4844103
    [No Abstract]   [Full Text] [Related]  

  • 55. L-dopa metabolism in man (with special reference to parkinsonism).
    Sandler M
    Sci Basis Med Annu Rev; 1972; ():161-73. PubMed ID: 4564341
    [No Abstract]   [Full Text] [Related]  

  • 56. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M
    Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239
    [No Abstract]   [Full Text] [Related]  

  • 57. Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation.
    Sharpe JA; Rewcastle NB; Lloyd KG; Hornykiewicz O; Hill M; Tasker RR
    J Neurol Sci; 1973 Jul; 19(3):275-86. PubMed ID: 4716845
    [No Abstract]   [Full Text] [Related]  

  • 58. Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
    Chase TN; Watanabe AM
    Neurology; 1972 Apr; 22(4):384-92. PubMed ID: 5062828
    [No Abstract]   [Full Text] [Related]  

  • 59. Metabolism and clinical assessment of L-dopa in parkinsonism.
    Ericsson AD; McCann D; Sharpless N; Reveno W
    Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of intracerebroventricularly administered somatostatin on brain monoamine turnover.
    Garcia-Sevilla JA; Magnusson T; Carlsson A
    Brain Res; 1978 Oct; 155(1):159-64. PubMed ID: 308386
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.